Scarica l'app Stockscreener
2.55
5.81%
0.14
Precedente Chiudi:
$2.41
Aprire:
$2.43
Volume 24 ore:
100.37K
Relative Volume:
0.52
Capitalizzazione di mercato:
$67.18M
Reddito:
-
Utile/perdita netta:
$-14.14M
Rapporto P/E:
-2.7717
EPS:
-0.92
Flusso di cassa netto:
$-12.64M
1 W Prestazione:
+13.84%
1M Prestazione:
+20.85%
6M Prestazione:
+8.51%
1 anno Prestazione:
+4.08%
Intervallo 1D:
$2.42
$2.59
Intervallo di 1 settimana:
$2.05
$2.59
Portata 52W:
$1.26
$3.00
Immix Biopharma Inc Stock (IMMX) Company Profile
Nome
Immix Biopharma Inc
Settore
Industria
Telefono
(888) 958-1084
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Confronta IMMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.59 | 67.18M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World
Immix Biopharma Attends FDA CEO Forum in Washington DC - GlobeNewswire
ImmixBio Joins Elite Pharma Leaders at FDA Commissioner's Strategic Forum on Drug Development - Stock Titan
Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential - Smartkarma
HC Wainwright Comments on Immix Biopharma Q1 Earnings - Defense World
Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright - Defense World
Immix Biopharma (IMMX) Achieves Significant Clinical Milestone w - GuruFocus
immix biopharma enters at-the-market offering agreement - Investing.com Australia
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial - Investing.com
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - Insider Monkey
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC - GuruFocus
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | IMMX Stock News - GuruFocus
Immix Biopharma Announces Primary Endpoint Met in positive - GlobeNewswire
Immix Biopharma stock soars to 52-week high of $2.99 By Investing.com - Investing.com India
Immix Biopharma reports high response rate in AL Amyloidosis trial By Investing.com - Investing.com South Africa
immix biopharma enters at-the-market offering agreement By Investing.com - Investing.com South Africa
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis - MarketScreener
Immix Biopharma stock soars to 52-week high of $2.99 - Investing.com Australia
Immix Biopharma Enters At The Market Offering Agreement - TipRanks
Immix Biopharma reports high response rate in AL Amyloidosis trial - Investing.com
Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025 - Nasdaq
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ... - Eagle-Tribune
Immix Biopharma — Positive newsflow continues for NEXICART-2 - Smartkarma
Immix Biopharma accelerates NEXICART-2 trial enrollment By Investing.com - Investing.com South Africa
Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Sto - GuruFocus
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus
Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com
Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World
Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia
Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com Nigeria
Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis - Nasdaq
Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis - The Manila Times
Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire
We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance
Immix Biopharma — Steady progress in Q125 - Smartkarma
Immix Biopharma Inc Azioni (IMMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immix Biopharma Inc Azioni (IMMX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
| Hsu Jason | Director |
Aug 21 '24 |
Buy |
2.23 |
15,000 |
33,390 |
837,200 |
| Hsu Jason | Director |
Aug 22 '24 |
Buy |
2.25 |
8,100 |
18,233 |
845,300 |
| Ng Carey | Director |
Aug 16 '24 |
Buy |
1.86 |
10,000 |
18,600 |
20,000 |
| Hsu Jason | Director |
Jul 24 '24 |
Buy |
2.15 |
6,000 |
12,877 |
822,200 |
| Hsu Jason | Director |
Jul 18 '24 |
Buy |
2.07 |
3,200 |
6,639 |
816,200 |
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):